Pulmonology

A higher proportion of newly diagnosed patients with PAH showed improved risk status after the initiation of the oral prostacyclin receptor agonist.

Investigators noted that the agonist was particularly effective in patients with severe PAH who were receiving spironolactone.

The letter pointed to a single deficiency related to an open inspection issue at a third-party facility.

The indication came via the Premarket Tobacco Product Application, which requires evidence of public health benefit and company agreement to post-marketing strategies that avoid young users.

There were no episode of gastrointestinal bleeding, transfusion of packed red blood cells, or octreotide infusions observed.

The long-term study from Denmark also found a strong association between gender and loss of asthma control, among other factors.

Michael Greenberg, MD, MPH, and Rick Nettles, MD, join Lungcast to discuss COVID-19 vaccine development, the 2021-22 flu season, RSV outbreaks, and more respiratory viruses.

Investigators found that exposure to surgical smoke and disinfectants over a long period of time led to increased risk of COPD in US female nurses.

The risk of TB was 48% higher in patients with diabetes compared to those without diabetes, while participants with IFG showed no increased risk of TB incidence.

Dr. Castro defines type 2 inflammation and the complications surrounding severe asthma, as well as several biomarkers including IgE levels, blood eosinophils, and exhaled nitric oxide.

The pulmonology and oncology expert panel returns for another discussion on lung cancer treatment challenges presented by the pandemic—and how the field can recover.

Dr. Castro and Dr. Rizzo discuss the evolving world of monoclonal antibodies for severe asthma. Plus, the ALA team discusses September's annual Asthma Peak Week, and what it means for reopening schools.

Investigators have found a negative association between the COPD and proton pump inhibitors through a familiar sequence symmetry analysis approach used to find associations between COPD and gastro-esophageal reflux disease.

Investigators found that intralymphatic immunotherapy of was not superior to placebo or other forms of allergen-specific immunotherapy, but felt continued research was warranted.

Avalglucosidase alfa-ngpt is an enzyme replacement therapy that reduces glycogen accumulation.

A new study suggests the Asthma Predictive Index can be used as a simple, noninvasive tool for determining asthma in preschoolers.

A new multi-year study shows that the immunotherapy increases tolerance of peanut products in patients with allergies.

Researchers report antibody responses in kidney transplant recipients and the impact of specific regiments utilized by select patients.

The FDA approved selexipag tablets for PAH in 2015.

The biologic can now be used as an add-on maintenance treatment for patients who have struggled with former treatment and surgeries.

Dr. Mazzocchi talks of the promising new cancer care therapies and how to properly inform and care for patients with cancer who may be overwhelmed.

Advancements in technology and the availability of resources for patients and doctors alike could mean a bright future for cardiology research.

Dr. Mazzocchi discusses the limits and benefits of immunotherapies, as well as the importance of genetic testing in determining cancer diagnosis and treatment in patients.

While investigators did not meet their primary endpoint in the study, results in former smokers within the trial were promising and prompted further research on the subgroup.

Andrea Mazzocchi, PhD, explains how tissue and blood samples can be used to improve detection, progression, and treatment for cancer in patients.

A leading author of a recent Oxford study speaks of azithromycin, its limitations in treating patients with COVID-19, and the importance of properly utilizing the antibiotic.

Using a participant group culled from several countries, investigators believe they have a better understanding on what contributes to uncontrolled allergic rhinitis and what it means for future patient care.

The co-founder and CEO of Known Medicine dissects the art and science of how profiling biomarkers, epigenetics and the microenvironment may provide the synergy needed to revolutionize the oncologic landscape.